Last reviewed · How we verify
TAO1, oral homeopathic antibodies
TAO1, oral homeopathic antibodies is a Small molecule drug developed by Theranor s.p.r.l. It is currently in Phase 1 development.
At a glance
| Generic name | TAO1, oral homeopathic antibodies |
|---|---|
| Sponsor | Theranor s.p.r.l |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAO1, oral homeopathic antibodies CI brief — competitive landscape report
- TAO1, oral homeopathic antibodies updates RSS · CI watch RSS
- Theranor s.p.r.l portfolio CI
Frequently asked questions about TAO1, oral homeopathic antibodies
What is TAO1, oral homeopathic antibodies?
TAO1, oral homeopathic antibodies is a Small molecule drug developed by Theranor s.p.r.l.
Who makes TAO1, oral homeopathic antibodies?
TAO1, oral homeopathic antibodies is developed by Theranor s.p.r.l (see full Theranor s.p.r.l pipeline at /company/theranor-s-p-r-l).
What development phase is TAO1, oral homeopathic antibodies in?
TAO1, oral homeopathic antibodies is in Phase 1.
Related
- Manufacturer: Theranor s.p.r.l — full pipeline